期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 213, 期 13, 页码 2885-2896出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20160662
关键词
-
资金
- Fondation pour la Recherche Medicale [FRM 2012 DEQ20120323704]
- Association Raoul Follereau
- Region Ile de France [dim 130027]
- Academy of Finland [289737]
- Sigrid Juselius Foundation
- Biocentrum Helsinki
- Pasteur-Roux Fellowship
- Academy of Finland (AKA) [289737] Funding Source: Academy of Finland (AKA)
Mycolactone, an immunosuppressive macrolide released by the human pathogen Mycobacterium ulcerans, was previously shown to impair Sec61-dependent protein translocation, but the underlying molecular mechanism was not identified. In this study, we show that mycolactone directly targets the alpha subunit of the Sec61 translocon to block the production of secreted and integral membrane proteins with high potency. We identify a single-amino acid mutation conferring resistance to mycolactone, which localizes its interaction site near the lumenal plug of Sec61 alpha. Quantitative proteomics reveals that during T cell activation, mycolactone-mediated Sec61 blockade affects a selective subset of secretory proteins including key signal-transmitting receptors and adhesion molecules. Expression of mutant Sec61 alpha in mycolactone-treated T cells rescued their homing potential and effector functions. Furthermore, when expressed in macrophages, the mycolactone-resistant mutant restored IFN-gamma receptor-mediated antimicrobial responses. Thus, our data provide definitive genetic evidence that Sec61 is the host receptor mediating the diverse immunomodulatory effects of mycolactone and identify Sec61 as a novel regulator of immune cell functions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据